Arena Pharmaceuticals Files European Marketing Authorization Application for Lorcaserin for Weight Control

Arena Pharmaceuticals, Inc. ARNA announced today the filing of a Marketing Authorization Application with the European Medicines Agency (EMA) for lorcaserin, an investigational drug candidate intended for weight control, including weight loss and maintenance of weight loss, in patients who are obese (BMI >30) or patients who are overweight (BMI >27) and have at least one weight-related co-morbid condition. Arena expects the EMA will accept the filing later this month and confirm the filing is sufficiently complete to permit a substantive review.